Phase 3 N=344 Staccato Loxapine in Agitated Patients With Schizophrenia
Patients With Schizophrenia and Acute Agitation
Primary: Change in PANSS-EC From Baseline — -5.5; -8.1; -8.6 units on a scale — p=0.0004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=120 Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
Agitation
Primary: Positive and Negative Syndrome Scale - Excited Component — 7.86; 14.93 PANSS SCORE
Phase 2 N=129 Staccato Loxapine in Agitation (Proof of Concept)
Schizophrenia
Primary: PANSS-EC Change From Baseline — -4.98; -6.71; -8.56 PANSS units — p=0.0880
Phase 3 N=67 Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Agitation
Primary: The Change of the Positive and Negative Symptom Scale Excited Component (PANSS-EC) Score From Baseline to 120 Minutes After First Injection — -10.2; -9.9 units on a…
Phase 4 N=72 A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
Agitation
Primary: Change in the PANSS-EC Score Among Participants From Baseline to 2 Hours After Administration of the Medication. — -11.0; -11.5 score on a scale — p=>0.05
Phase 3 N=380 Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
Agitation · Schizophrenia · Schizo Affective Disorder
Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — 17.5; 17.6; 17.6; -8.4 score on a scale — p=<0.0001
Phase 3 N=34 A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) — -4.7; -4.6 units on a…
Phase 3 N=468 Brexpiprazole in Patients With Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in PANSS Total Score — -15.9; -20.0; -24.0 units on a scale — p=0.0560
Phase 3 N=91 A Study of Olanzapine in Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection…
Phase 4 N=35 Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) Score — -7.5 Scores on a scale
Phase 3 N=314 Staccato Loxapine in Agitated Patients With Bipolar Disorder
Bipolar I Disorder
Primary: Change in PANSS Excited Component (PEC) Score From Baseline Following Dose #1 of Staccato Loxapine, Compared With Placebo — -4.9; -8.1; -9.0 units on a scale — p=<0.0001
Phase 2 N=259 An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — 98.1; 97.7; 97.4; 97.2 units on a scale — p=0.2053
Phase 2 N=77 Treatment of Psychosis and Agitation in Alzheimer's Disease
Alzheimer's Disease · Psychosis · Agitation
Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53
Phase 3 N=401 A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -23.9; -22.8; -17.5 units on a scale — p=<0.001
Phase 3 N=376 A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
Schizophrenia
Primary: Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Scores at 72 Hours — -17.32; -18.44 scores on a scale
Phase 4 N=110 Antipsychotic Discontinuation in Alzheimer's Disease
Alzheimer Disease · Psychotic Disorders · Agitation
Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02
Phase 4 N=491 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
Schizophrenia
Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…
Phase 3 N=187 Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
Phase 4 N=450 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
Schizophrenia
Primary: Time to First Treatment Failure — 416; 226 Days
Phase 3 N=186 Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
Schizophrenia
Primary: Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse. — 19.39; 37.50 relapse rate(percentage of participants)…
Phase 3 N=302 Aripiprazole in Adolescents With Schizophrenia
Schizophrenia
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Total Score — -26.7; -28.6; -21.2 points — p=0.05
Phase 3 N=382 Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
Schizoaffective Disorder · Schizophrenia
Primary: Hospitalization-free Survival - Time to Event — NA; 1.97 years — p=0.39
Phase 4 N=29 Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
Bipolar Disorder · Schizophrenia · Agitation,Psychomotor
Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — -10.4; -10.0; -10.1; -9.8 score on a scale
Phase 3 N=360 A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
Schizophrenia
Primary: Change From Baseline in PANSS Total Score at Day 42 — -17.4; -21.7; -21.6; -16.2 score on a scale — p=0.6043
Phase 3 N=508 Safety and Efficacy of MP-214 in Patients With Schizophrenia
Schizophrenia
Primary: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 — -10.4; -13.8; -14.0; -20.2 units on a scale
Phase 2 N=359 Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 4 in the PANSS Total Score — -14.28; -13.95; -16.08; -9.27 score on a scale — p=0.0009
Phase 2 N=245 A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -9.7; -17.2 Units on a scale — p=0.001
Phase 3 N=340 Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Schizophrenia
Primary: Mean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score. — -8.9; -5.0; -15.2; -8.3 Units on a scale — p=0.0005
Phase 3 N=48 Risperdal Consta for Bipolar Disorder
Bipolar I Disorder
Primary: Evaluate the Number of Clinical Events (Pooled) Occurring Between 3-15 Months Following a Switch/Stabilization of the Antipsychotic Agents Among Patients Who Receive…
Phase 3 N=623 A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Schizophrenia
Primary: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score — -20.9; -21.8; -9.8 units on a scale — p=<0.001